Latest Cutaneous Lupus Erythematosus News

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.